T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan plc
AGN
|
+$2.6B |
| 2 |
BNY
Bank of New York Mellon
BNY
|
+$1.1B |
| 3 |
Elevance Health
ELV
|
+$903M |
| 4 |
DD
Du Pont De Nemours E I
DD
|
+$873M |
| 5 |
Medtronic
MDT
|
+$868M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan Inc
AGN
|
+$3.89B |
| 2 |
COV
COVIDIEN PLC COM SHS NEW (IRELAND)
COV
|
+$1.06B |
| 3 |
CFN
CAREFUSION CORPORATION
CFN
|
+$946M |
| 4 |
Aptiv
APTV
|
+$886M |
| 5 |
KSU
Kansas City Southern
KSU
|
+$662M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 21.57% |
| 2 | Consumer Discretionary | 13.93% |
| 3 | Financials | 13.16% |
| 4 | Industrials | 12.02% |
| 5 | Technology | 10.24% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
151
Willis Towers Watson
WTW
$27.3B
| $828M | 0.17% |
6,487,512
+2,404,245
| +59% | +$295M |
|
|
CXO
152
DELISTED
CONCHO RESOURCES INC.
CXO
| $822M | 0.17% |
7,088,641
-968,779
| -12% | -$106M |
|
153
HCA Healthcare
HCA
$94.3B
| $821M | 0.17% |
10,918,242
+273,837
| +3% | +$19.7M |
|
154
Sensata Technologies
ST
$6.14B
| $800M | 0.17% |
13,926,316
+1,734,940
| +14% | +$92.3M |
|
155
IBM
IBM
$212B
| $794M | 0.16% |
5,171,433
-116,352
| -2% | -$17.6M |
|
156
Bath & Body Works
BBWI
$3.32B
| $778M | 0.16% |
10,201,778
-820,506
| -7% | -$59.3M |
|
157
IDEX
IEX
$17B
| $764M | 0.16% |
10,079,822
+166,183
| +2% | +$12.5M |
|
158
Ameriprise Financial
AMP
$43.5B
| $759M | 0.16% |
5,799,414
-12,482
| -0.2% | -$1.64M |
|
159
Zoetis
ZTS
$29.4B
| $757M | 0.16% |
16,350,410
-1,071,544
| -6% | -$48.3M |
|
160
American Express
AXP
$209B
| $751M | 0.16% |
9,609,182
-2,888,135
| -23% | -$240M |
|
161
VeriSign
VRSN
$26B
| $743M | 0.15% |
11,099,869
-753,980
| -6% | -$45.8M |
|
162
McDonald's
MCD
$167B
| $733M | 0.15% |
7,524,652
+2,409,026
| +47% | +$229M |
|
|
IHS
163
DELISTED
IHS INC CL-A COM STK
IHS
| $733M | 0.15% |
6,442,384
-63,834
| -1% | -$7.37M |
|
164
Las Vegas Sands
LVS
$25.3B
| $732M | 0.15% |
13,303,480
-1,421,368
| -10% | -$79.2M |
|
|
N
165
DELISTED
Netsuite Inc
N
| $730M | 0.15% |
7,867,267
+406,418
| +5% | +$40.3M |
|
166
Union Pacific
UNP
$163B
| $727M | 0.15% |
6,714,584
-403,679
| -6% | -$47.4M |
|
167
Entergy
ETR
$47.1B
| $726M | 0.15% |
18,747,054
-5,555,346
| -23% | -$228M |
|
168
Ecolab
ECL
$78.3B
| $722M | 0.15% |
6,316,068
-3,300,168
| -34% | -$362M |
|
169
CNX Resources
CNX
$4.85B
| $718M | 0.15% |
30,885,764
+1,893,292
| +7% | +$48.3M |
|
170
Amgen
AMGN
$224B
| $713M | 0.15% |
4,460,420
-157,461
| -3% | -$24.8M |
|
171
United Parcel Service
UPS
$79.9B
| $710M | 0.15% |
7,325,736
-136,346
| -2% | -$14M |
|
172
Puma Biotechnology
PBYI
$504M
| $708M | 0.15% |
2,998,090
+231,389
| +8% | +$49.5M |
|
173
Sysco
SYY
$37.6B
| $707M | 0.15% |
18,750,725
-73,881
| -0.4% | -$2.91M |
|
|
WP
174
DELISTED
Worldpay, Inc.
WP
| $706M | 0.15% |
18,729,171
+578,376
| +3% | +$20.9M |
|
175
Western Union
WU
$1.93B
| $702M | 0.14% |
33,716,250
+2,060,501
| +7% | +$38.4M |
|
Similar funds
T. Rowe Price Associates's Q1 2015 Portfolio in Review
As of Q1 2015, T. Rowe Price Associates held 2,630 positions worth $484B, up 2.8% from $471B the previous quarter. Its ten largest holdings account for 13% of the portfolio.
T. Rowe Price Associates's Q1 2015 filing shows 93 new, 1,078 increased, 887 reduced and 93 closed positions. Its largest new stake was ACTAVIS PLC Pfd Conv Ser A (Irl): 516,600 shares worth $532M. The largest sale was Allergan Inc, an estimated $3.89B.
By sector, the portfolio is most concentrated in Healthcare at 22% of assets, up from 20% a quarter earlier, followed by Consumer Discretionary and Financials.
- T. Rowe Price Associates's largest Q1 2015 buy was ACTAVIS PLC Pfd Conv Ser A (Irl): 516,600 shares worth $532M.
- T. Rowe Price Associates added most to Allergan plc in Q1 2015, an estimated $2.6B increase.
- T. Rowe Price Associates's biggest Q1 2015 reduction was Aptiv, cutting an estimated $886M.
- T. Rowe Price Associates fully exited Allergan Inc in Q1 2015, selling an estimated $3.89B.
- T. Rowe Price Associates's ten largest holdings make up 13% of its $484B portfolio in Q1 2015.
- T. Rowe Price Associates opened 93 new positions and closed 93 in Q1 2015.
- T. Rowe Price Associates's portfolio value rose 2.8% quarter-over-quarter to $484B.
Based on T. Rowe Price Associates's 13F filing for Q1 2015, filed 15 May 2015.